US FDA blesses BMS kidney transplant drug
This article was originally published in Scrip
Executive Summary
The US FDA on 15 June granted marketing approval for Bristol-Myers Squibb's Nulojix (belatacept) for use with other immunosuppressants – basiliximab, mycophenolate mofetil and corticosteroids – as a therapy to prevent organ rejection after a kidney transplant.